SlideShare a Scribd company logo
Treatment of Sexual dysfunction associated with CVD Graham Jackson  Consultant Cardiologist  Guy’s & St Thomas’ Hospital, London, UK.
 
Recommendation 1 ,[object Object],[object Object]
ED Predicts coronary events 1400 men 40-75,  with no known CAD 10yr  follow up  Inman et al Mayo Clin Pr 2009;84:108-113  Age Group ED at baseline No baseline ED 40-49 48.52 (1.23-269.26) 0.94 (0.02-5.21) 50-59 27.15  (7.40-69.56) 5.09  (3.38-7.38 ) 60-69 23.97  (11.49-44.10) 10.72  (7.62-14.66) 70+ 29.63  (19.37-43.75) 23.30  (17.18-30.89) CAD events per 1000 pt years with CI interval Inman et al Mayo Clin Pr 2009
ED As A Predictor for Subsequent CVD Events: A Linked Data Study ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Chew et al JSM 2010;7:192-202
Meet Jorge ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Investigations ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Radiologist’s Comment ,[object Object]
 
Recommendation 2 ,[object Object],[object Object],[object Object],[object Object]
The Temporal Relationship Between ED and CVD ,[object Object],[object Object],[object Object],[object Object],[object Object],Hodges et al Int J Clin. Pract 2007;61:2019-25 In half the men there were missed opportunities to assess CVD risk “ Men with ED should be specifically targeted for CVD preventative strategies in terms of lifestyle changes and pharmacological treatments”
ED Prevalence, Time of Onset in 300 consecutive men with acute chest pain and CAD ,[object Object],[object Object],[object Object],[object Object],Montorsi et al  Eur Urol  2003;44:360-5
Time interval between ED onset and CAD Montorsi F, et al .  Eur Urol 2003 ,[object Object],Montorsi P, et al. Eur Heart J 2006 In almost all pts,  ED comes before CAD by an average of   2 up to 3 years
Recommendation 3 ,[object Object],[object Object]
Erectile Dysfunction and Mortality ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ED predicts CVD events in high risk patients receiving Telmisartan, Ramipril or both ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical perspective ,[object Object],Circulation 2010;121:1446
Recommendation 4 ,[object Object],[object Object],[object Object],[object Object]
Figure 1. Management of man with ED and no known CVD *Determine ED severity based on International Index of Erectile Function (IIEF): mild 17-21; mild to moderate 12-16; moderate 8-11; severe 1-7  Consider cardiac evaluation if severe irrespective of Framingham score. † Incorporate age, gender, total cholesterol, HDL cholesterol, smoking, systolic BP, BP therapy (see appendix sample calculation) Sexual Enquiry of All Men E.D. (No known CVD)* Essential Checks:  Age, BP, glucose, lipids, testosterone, smoking Additional Checks: BMI, waist circumference, exercise, alcohol, diet, family history Framingham Risk † Low (<10%) Intermediate (10-20%) High (>20%) Lifestyle Advice Lifestyle advice, medication and non-invasive risk evaluation (e.g. stress testing) Lifestyle advice, medication, and cardiologist
Meet David aged 50 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],What else would you like to know?
David  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],What could he have?
Metabolic Syndrome ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Increased risk of CAD, stroke and future diabetes Any other information or tests?
 
Metabolic Syndrome increases CV morbidity and mortality 21 9 4.8 5.5 2.1 1.4 0 5 10 15 20 25 CHD Previous MI Previous stroke 4.6 2.2 12 18 0 5 10 15 20 25 Total mortality CV mortality Incidence   (%) Prevalence   (%) Metabolic syndrome present Metabolic syndrome absent Isomaa B,  et al. Diabetes Care  2001; 24: 683–689 . p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 Morbidity Mortality
Exercise ECG ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
ED exercise ECG and CT angio ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Results ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Recommendation 5 ,[object Object],[object Object],[object Object],[object Object]
Risk Factor Modification and ED ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Esposito et al, JAMA, 2004, 291: 2978-3012
Risk Factor Modification and ED Esposito et al, JAMA, 2004, 291: 2978-3012
Recommendation 6 ,[object Object],[object Object],[object Object]
ASCOT:  Baseline Characteristics Age* (years) Male (%) Caucasian (%) SBP* (mm Hg) DBP* (mm Hg) TC* (mmol/L [mg/dL]) LDL-C* (mmol/L [mg/dL])  TG* (mmol/L [mg/dL]) HDL-C* (mmol/L [mg/dL]) Number of risk factors* 63.1 ± 8.5 81.1 94.6 164.2 ± 17.7 95.0 ± 10.3 5.5 ± 0.8 (213 ± 31) 3.4 ± 0.7 (131 ± 27) 1.7 ± 0.9 (150 ± 80)  1.3 ± 0.4 (50 ± 27)  3.7 ± 0.9 Characteristic Atorvastatin (n=5168) 63.2 ± 8.6 81.3 94.7 164.2 ± 18.0 95.0 ± 10.3 5.5 ± 0.8 (213 ± 31) 3.4 ± 0.7 (131 ± 27) 1.6 ± 0.9 (142 ± 80)  1.3 ± 0.4 (50 ± 27)  3.7 ± 0.9 Placebo (n=5137 ) *Mean ± SD Sever PS, Dahlöf B, Poulter N, Wedel H, et al, for the ASCOT Investigators. Lancet. 2003;361:1149-58
ASCOT-LLA was Terminated Early ,[object Object],Sever PS, et al, and the ASCOT Investigators.  Lancet.  2003;361:1149-1158. ,[object Object]
Confirmation that ED increases risk of CVD in Diabetes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CARDS (n=2838) ,[object Object],[object Object],[object Object],[object Object]
Obesity Diabetes Hypertension Dyslipidemia ED: BAROMETER OF MEN ’ S HEALTH: The Deadly Quartet
Recommendation 7 ,[object Object],[object Object]
Metabolic equivalent (METs) of Selected Daily Activity compared to Sexual Activity
“  The same old story…” Cost of Sexual Activity:  The case for a distinction “ New fling” Familiar partner Unfamiliar partner + Familiar setting + Unfamiliar setting METS 2-3 METS 5-6 + Familiar meal + Unfamiliar meal
Cardiovascular Changes during Sexual Activity Simple everyday guidelines Walking 1 mile in 20’     3.5 METS Briskly climbing 2 flights of stairs (20 steps in 10 seconds)     3 METS “ The stair-climbing test” (Larson, 1980) Digging in the garden     5 METS
Figure 2. Management of ED in patient with known CVD *Based on patient history per Princeton II (Kostis et al. 2005) † Sexual activity equivalent to walking 1 mile on the flat in 20 minutes, briskly climbing 2 flights of stairs (10 seconds) ‡ Sexual activity equivalent to 4 minutes of the Bruce treadmill protocol Sexual Enquiry of All Men E.D. and known CVD Clinical evaluation to determine CV risk with sexual activity*  Low CV risk Intermediate or indeterminate risk High risk Exercise ability † Exercise stress testing ‡ Sexual activity deferred; see cardiologist Initiate/resume sexual activity, treat ED Low risk High risk
Recommendation 8 ,[object Object],[object Object],[object Object],[object Object]
Recommendation 9 ,[object Object],[object Object],[object Object],[object Object]
Low Testosterone associated with increase CV and all cause mortality Khaw et al ( Circulation.  2007;116:2694-2701.) ,[object Object],[object Object]
Recommendation 10 ,[object Object],[object Object],[object Object]
IPASS – 763 men receiving 2788 injections on NEBIDO 1,000mg ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Recommendation 11 ,[object Object],[object Object]
Conclusion  ,[object Object],[object Object],[object Object]
Take Home Message  E.D. E rectile  D ysfunction ED ucation E arly  D etection E ndothelial  D ysfunction E arly  D eath
A final thought..... ,[object Object]
 

More Related Content

What's hot

Aspirin use for the primary prevention of cardiovascular disease and colorect...
Aspirin use for the primary prevention of cardiovascular disease and colorect...Aspirin use for the primary prevention of cardiovascular disease and colorect...
Aspirin use for the primary prevention of cardiovascular disease and colorect...
jegan mohan
 
Managing the Myths in Lipid Management
Managing the Myths in Lipid ManagementManaging the Myths in Lipid Management
Managing the Myths in Lipid Management
ahvc0858
 
Frequency of metabolic syndrome and its’ various
Frequency of metabolic syndrome and its’ variousFrequency of metabolic syndrome and its’ various
Frequency of metabolic syndrome and its’ various
Samiullah Shaikh
 
Cilostazol treatment intermittent claudication
Cilostazol   treatment intermittent claudicationCilostazol   treatment intermittent claudication
Cilostazol treatment intermittent claudication
Kaloyan Stamenov
 
Fatty Acids and their role in Cardiometabolic Health
Fatty Acids and their role in Cardiometabolic HealthFatty Acids and their role in Cardiometabolic Health
Fatty Acids and their role in Cardiometabolic Health
Arindam Pande
 
Cardio updates 2019 power point template
Cardio updates 2019 power point templateCardio updates 2019 power point template
Cardio updates 2019 power point template
Haytham Ghareeb
 
What next after metformin dpp4 vs su
What next after metformin dpp4 vs suWhat next after metformin dpp4 vs su
What next after metformin dpp4 vs su
Veerendra Singh
 
Emergency Cardiology
Emergency CardiologyEmergency Cardiology
Emergency Cardiology
Narenthorn EMS Center
 
Heart Failure in Women: More than EF?
Heart Failure in Women: More than EF?Heart Failure in Women: More than EF?
Heart Failure in Women: More than EF?
ahvc0858
 
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
Dr Vivek Baliga
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“
Arindam Pande
 
Cap nhat lipid 2017
Cap nhat lipid 2017Cap nhat lipid 2017
Cap nhat lipid 2017
khacleson
 
Coronary Artery Disease - The Benefits of Exercise
Coronary Artery Disease - The Benefits of ExerciseCoronary Artery Disease - The Benefits of Exercise
Coronary Artery Disease - The Benefits of Exercise
Bond University HSM Faculty
 
ACS & AMI Update WIN Program - SCAI 2010
ACS & AMI UpdateWIN Program - SCAI 2010ACS & AMI UpdateWIN Program - SCAI 2010
ACS & AMI Update WIN Program - SCAI 2010
TriMed Media Group
 
Cancer related anemia
Cancer related anemiaCancer related anemia
Cancer related anemia
Prof. Shad Salim Akhtar
 
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CADTHE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
Sunil Wadhwa
 
Lipid lowering trials ppt
Lipid lowering trials pptLipid lowering trials ppt
Lipid lowering trials ppt
Navin Agrawal
 
Dm medications cv safety
Dm medications cv safetyDm medications cv safety
Dm medications cv safety
Mohammad Othman Daoud
 
Strive Teleconf Presentation Apr11 2007
Strive Teleconf Presentation Apr11 2007Strive Teleconf Presentation Apr11 2007
Strive Teleconf Presentation Apr11 2007
MedicineAndHealthCancer
 
CVD Egypt Clinical Diabetes Reprint Summer 2010
CVD Egypt Clinical Diabetes Reprint Summer 2010CVD Egypt Clinical Diabetes Reprint Summer 2010
CVD Egypt Clinical Diabetes Reprint Summer 2010
Mahmoud IBRAHIM
 

What's hot (20)

Aspirin use for the primary prevention of cardiovascular disease and colorect...
Aspirin use for the primary prevention of cardiovascular disease and colorect...Aspirin use for the primary prevention of cardiovascular disease and colorect...
Aspirin use for the primary prevention of cardiovascular disease and colorect...
 
Managing the Myths in Lipid Management
Managing the Myths in Lipid ManagementManaging the Myths in Lipid Management
Managing the Myths in Lipid Management
 
Frequency of metabolic syndrome and its’ various
Frequency of metabolic syndrome and its’ variousFrequency of metabolic syndrome and its’ various
Frequency of metabolic syndrome and its’ various
 
Cilostazol treatment intermittent claudication
Cilostazol   treatment intermittent claudicationCilostazol   treatment intermittent claudication
Cilostazol treatment intermittent claudication
 
Fatty Acids and their role in Cardiometabolic Health
Fatty Acids and their role in Cardiometabolic HealthFatty Acids and their role in Cardiometabolic Health
Fatty Acids and their role in Cardiometabolic Health
 
Cardio updates 2019 power point template
Cardio updates 2019 power point templateCardio updates 2019 power point template
Cardio updates 2019 power point template
 
What next after metformin dpp4 vs su
What next after metformin dpp4 vs suWhat next after metformin dpp4 vs su
What next after metformin dpp4 vs su
 
Emergency Cardiology
Emergency CardiologyEmergency Cardiology
Emergency Cardiology
 
Heart Failure in Women: More than EF?
Heart Failure in Women: More than EF?Heart Failure in Women: More than EF?
Heart Failure in Women: More than EF?
 
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“
 
Cap nhat lipid 2017
Cap nhat lipid 2017Cap nhat lipid 2017
Cap nhat lipid 2017
 
Coronary Artery Disease - The Benefits of Exercise
Coronary Artery Disease - The Benefits of ExerciseCoronary Artery Disease - The Benefits of Exercise
Coronary Artery Disease - The Benefits of Exercise
 
ACS & AMI Update WIN Program - SCAI 2010
ACS & AMI UpdateWIN Program - SCAI 2010ACS & AMI UpdateWIN Program - SCAI 2010
ACS & AMI Update WIN Program - SCAI 2010
 
Cancer related anemia
Cancer related anemiaCancer related anemia
Cancer related anemia
 
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CADTHE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
 
Lipid lowering trials ppt
Lipid lowering trials pptLipid lowering trials ppt
Lipid lowering trials ppt
 
Dm medications cv safety
Dm medications cv safetyDm medications cv safety
Dm medications cv safety
 
Strive Teleconf Presentation Apr11 2007
Strive Teleconf Presentation Apr11 2007Strive Teleconf Presentation Apr11 2007
Strive Teleconf Presentation Apr11 2007
 
CVD Egypt Clinical Diabetes Reprint Summer 2010
CVD Egypt Clinical Diabetes Reprint Summer 2010CVD Egypt Clinical Diabetes Reprint Summer 2010
CVD Egypt Clinical Diabetes Reprint Summer 2010
 

Similar to Erectile Dysfunction

Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence  Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence
SYEDRAZA56411
 
download-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptxdownload-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptx
UmaShanksr
 
Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?
My Healthy Waist
 
Statin trials
Statin trials Statin trials
Statin trials
Saitej Reddy
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
MedicineAndFamily
 
Hypertension
HypertensionHypertension
Hypertension
Anac09
 
2008.02.12 Massie Hyperlipidemia
2008.02.12    Massie   Hyperlipidemia2008.02.12    Massie   Hyperlipidemia
2008.02.12 Massie Hyperlipidemia
MedicineAndHealthCancer
 
Role of aci ccb in htn management
Role of aci ccb in htn managementRole of aci ccb in htn management
Role of aci ccb in htn management
Dr. Adel El Naggar
 
Weight diabetes and metabolic problems in patients taking atypical antipsycho...
Weight diabetes and metabolic problems in patients taking atypical antipsycho...Weight diabetes and metabolic problems in patients taking atypical antipsycho...
Weight diabetes and metabolic problems in patients taking atypical antipsycho...
Alex J Mitchell
 
ueda2013 primary prevention-d.lobna
ueda2013 primary prevention-d.lobnaueda2013 primary prevention-d.lobna
ueda2013 primary prevention-d.lobna
ueda2015
 
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
LupusNY
 
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapyECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
European School of Oncology
 
Metabolic syndrome: an Asian perspective
Metabolic syndrome: an Asian perspectiveMetabolic syndrome: an Asian perspective
Metabolic syndrome: an Asian perspective
My Healthy Waist
 
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
GlobalProvidence
 
LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”
Arindam Pande
 
International Journal of Nephrology & Therapeutics
International Journal of Nephrology & TherapeuticsInternational Journal of Nephrology & Therapeutics
International Journal of Nephrology & Therapeutics
SciRes Literature LLC. | Open Access Journals
 
Blood sugar
Blood sugarBlood sugar
Blood sugar
DMS Library
 
Coronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
Coronary Artery Disease in Epidemic Proportions in the Indian SubcontinentCoronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
Coronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
drmjavedakhtar
 
Ndei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes EpidemiologyNdei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes Epidemiology
david7s
 
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
MedicineAndFamily
 

Similar to Erectile Dysfunction (20)

Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence  Dyslipidemia -Assessment and management based on evidence
Dyslipidemia -Assessment and management based on evidence
 
download-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptxdownload-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptx
 
Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?
 
Statin trials
Statin trials Statin trials
Statin trials
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
 
Hypertension
HypertensionHypertension
Hypertension
 
2008.02.12 Massie Hyperlipidemia
2008.02.12    Massie   Hyperlipidemia2008.02.12    Massie   Hyperlipidemia
2008.02.12 Massie Hyperlipidemia
 
Role of aci ccb in htn management
Role of aci ccb in htn managementRole of aci ccb in htn management
Role of aci ccb in htn management
 
Weight diabetes and metabolic problems in patients taking atypical antipsycho...
Weight diabetes and metabolic problems in patients taking atypical antipsycho...Weight diabetes and metabolic problems in patients taking atypical antipsycho...
Weight diabetes and metabolic problems in patients taking atypical antipsycho...
 
ueda2013 primary prevention-d.lobna
ueda2013 primary prevention-d.lobnaueda2013 primary prevention-d.lobna
ueda2013 primary prevention-d.lobna
 
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
 
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapyECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
ECCLU 2011 - B. Tombal - Side-effects of anti-androgen therapy
 
Metabolic syndrome: an Asian perspective
Metabolic syndrome: an Asian perspectiveMetabolic syndrome: an Asian perspective
Metabolic syndrome: an Asian perspective
 
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
pdfslide.net_adam-syndrome-androgen-deficiency-in-the-aging-man-andropause-56...
 
LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”
 
International Journal of Nephrology & Therapeutics
International Journal of Nephrology & TherapeuticsInternational Journal of Nephrology & Therapeutics
International Journal of Nephrology & Therapeutics
 
Blood sugar
Blood sugarBlood sugar
Blood sugar
 
Coronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
Coronary Artery Disease in Epidemic Proportions in the Indian SubcontinentCoronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
Coronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
 
Ndei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes EpidemiologyNdei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes Epidemiology
 
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
 

Recently uploaded

Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
Gokuldas Hospital
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
DRPREETHIJAMESP
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 

Recently uploaded (20)

Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 

Erectile Dysfunction

  • 1. Treatment of Sexual dysfunction associated with CVD Graham Jackson Consultant Cardiologist Guy’s & St Thomas’ Hospital, London, UK.
  • 2.  
  • 3.
  • 4. ED Predicts coronary events 1400 men 40-75, with no known CAD 10yr follow up Inman et al Mayo Clin Pr 2009;84:108-113 Age Group ED at baseline No baseline ED 40-49 48.52 (1.23-269.26) 0.94 (0.02-5.21) 50-59 27.15 (7.40-69.56) 5.09 (3.38-7.38 ) 60-69 23.97 (11.49-44.10) 10.72 (7.62-14.66) 70+ 29.63 (19.37-43.75) 23.30 (17.18-30.89) CAD events per 1000 pt years with CI interval Inman et al Mayo Clin Pr 2009
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.  
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19. Figure 1. Management of man with ED and no known CVD *Determine ED severity based on International Index of Erectile Function (IIEF): mild 17-21; mild to moderate 12-16; moderate 8-11; severe 1-7 Consider cardiac evaluation if severe irrespective of Framingham score. † Incorporate age, gender, total cholesterol, HDL cholesterol, smoking, systolic BP, BP therapy (see appendix sample calculation) Sexual Enquiry of All Men E.D. (No known CVD)* Essential Checks: Age, BP, glucose, lipids, testosterone, smoking Additional Checks: BMI, waist circumference, exercise, alcohol, diet, family history Framingham Risk † Low (<10%) Intermediate (10-20%) High (>20%) Lifestyle Advice Lifestyle advice, medication and non-invasive risk evaluation (e.g. stress testing) Lifestyle advice, medication, and cardiologist
  • 20.
  • 21.
  • 22.
  • 23.  
  • 24. Metabolic Syndrome increases CV morbidity and mortality 21 9 4.8 5.5 2.1 1.4 0 5 10 15 20 25 CHD Previous MI Previous stroke 4.6 2.2 12 18 0 5 10 15 20 25 Total mortality CV mortality Incidence (%) Prevalence (%) Metabolic syndrome present Metabolic syndrome absent Isomaa B, et al. Diabetes Care 2001; 24: 683–689 . p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 Morbidity Mortality
  • 25.
  • 26.  
  • 27.
  • 28.
  • 29.
  • 30.
  • 31. Risk Factor Modification and ED Esposito et al, JAMA, 2004, 291: 2978-3012
  • 32.
  • 33. ASCOT: Baseline Characteristics Age* (years) Male (%) Caucasian (%) SBP* (mm Hg) DBP* (mm Hg) TC* (mmol/L [mg/dL]) LDL-C* (mmol/L [mg/dL]) TG* (mmol/L [mg/dL]) HDL-C* (mmol/L [mg/dL]) Number of risk factors* 63.1 ± 8.5 81.1 94.6 164.2 ± 17.7 95.0 ± 10.3 5.5 ± 0.8 (213 ± 31) 3.4 ± 0.7 (131 ± 27) 1.7 ± 0.9 (150 ± 80) 1.3 ± 0.4 (50 ± 27) 3.7 ± 0.9 Characteristic Atorvastatin (n=5168) 63.2 ± 8.6 81.3 94.7 164.2 ± 18.0 95.0 ± 10.3 5.5 ± 0.8 (213 ± 31) 3.4 ± 0.7 (131 ± 27) 1.6 ± 0.9 (142 ± 80) 1.3 ± 0.4 (50 ± 27) 3.7 ± 0.9 Placebo (n=5137 ) *Mean ± SD Sever PS, Dahlöf B, Poulter N, Wedel H, et al, for the ASCOT Investigators. Lancet. 2003;361:1149-58
  • 34.
  • 35.
  • 36.
  • 37. Obesity Diabetes Hypertension Dyslipidemia ED: BAROMETER OF MEN ’ S HEALTH: The Deadly Quartet
  • 38.
  • 39. Metabolic equivalent (METs) of Selected Daily Activity compared to Sexual Activity
  • 40. “ The same old story…” Cost of Sexual Activity: The case for a distinction “ New fling” Familiar partner Unfamiliar partner + Familiar setting + Unfamiliar setting METS 2-3 METS 5-6 + Familiar meal + Unfamiliar meal
  • 41. Cardiovascular Changes during Sexual Activity Simple everyday guidelines Walking 1 mile in 20’  3.5 METS Briskly climbing 2 flights of stairs (20 steps in 10 seconds)  3 METS “ The stair-climbing test” (Larson, 1980) Digging in the garden  5 METS
  • 42. Figure 2. Management of ED in patient with known CVD *Based on patient history per Princeton II (Kostis et al. 2005) † Sexual activity equivalent to walking 1 mile on the flat in 20 minutes, briskly climbing 2 flights of stairs (10 seconds) ‡ Sexual activity equivalent to 4 minutes of the Bruce treadmill protocol Sexual Enquiry of All Men E.D. and known CVD Clinical evaluation to determine CV risk with sexual activity* Low CV risk Intermediate or indeterminate risk High risk Exercise ability † Exercise stress testing ‡ Sexual activity deferred; see cardiologist Initiate/resume sexual activity, treat ED Low risk High risk
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50. Take Home Message E.D. E rectile D ysfunction ED ucation E arly D etection E ndothelial D ysfunction E arly D eath
  • 51.
  • 52.  

Editor's Notes

  1. In September 2002, the Data Safety Monitoring Board (DSMB) recommended that the double-blind, cholesterol-lowering study arm be terminated on the grounds that atorvastatin demonstrated a highly significant reduction in the primary end point as well as a significant reduction in the secondary end point of stroke. The Steering Committee endorsed the recommendation of the DSMB, and the lipid arm was closed after a median follow-up of 3.3 years. The overall BP study is ongoing. Sever PS, Dahlöf B, Poulter NR, et al, and the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
  2. -- DESPITE– THE NUMBER, OF ORGANIC FACTORS, AND DISEASES, THAT MAY PRE-DETERMINE MSD, -- WE CAN DEMONSTRATE, THE INFLUENCE, OF PSYCHOSOCIAL FACTORS.